Microbot Medical Inc. (MBOT) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended September 30, 2024. Microbot Medical Inc. is a pre-clinical medical device company developing the LIBERTY® Endovascular Robotic Surgical System, a fully disposable robotic system for endovascular procedures. The company has not yet generated revenue from operations and remains in the research and development phase.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(3.215) million | $(2.446) million | $(8.051) million | $(7.586) million |
| Loss Per Share (Diluted) | $(0.20) | $(0.21) | $(0.53) | $(0.79) |
| Cash & Cash Equivalents | $0.479 million (Sep 30, 2024) vs $2.468 million (Dec 31, 2023) | |||
| Marketable Securities | ||||
| Total Liquidity | $4.338 million (Sep 30, 2024) | |||
| Operating Cash Flow (YTD) | $(7.136) million | $(6.712) million | ||
| Financing Cash Flow (YTD) | $5.104 million | $6.558 million |
Material Changes vs. Prior Period
- Increased Operating Expenses: Research and Development (R&D) expenses increased by $0.448 million in Q3 2024 compared to Q3 2023, driven by higher clinical study and payroll costs following the cessation of a cost-reduction plan implemented in 2023. General and Administrative (G&A) expenses rose by $0.308 million due to increased payroll.
- Legal Settlement Resolution: The company settled a 2017 financing lawsuit in Q1 2024. The settlement involved a cash payment of $1.1 million (covered by insurance) and the issuance of 1,005,965 shares of common stock. The liability recorded in 2023 was fully resolved in 2024.
- Capital Raises: The company raised approximately $5.1 million in net proceeds from financing activities in the first nine months of 2024, including registered direct offerings and an At-the-Market (ATM) program. This is a decrease from the $6.6 million raised in the same period in 2023.
- Share Count: Outstanding shares increased from 11.7 million (Dec 31, 2023) to 16.7 million (Sep 30, 2024) due to equity issuances for capital raises and legal settlements.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management states that conditions raise substantial doubt about the company's ability to continue as a going concern. They estimate sufficient funds for operations for less than one year and will require additional capital to continue R&D and regulatory efforts.
- Clinical Progress: The company received FDA approval for its Investigational Device Exemption (IDE) in June 2024 and successfully completed enrollment and follow-up for all patients in its pivotal human clinical trial by October 2024. A 510(k) submission is anticipated by the end of 2024, with clearance expected in H1 2025.
- War in Israel: Operations are primarily based in Israel. While no material adverse effect has been determined to date, ongoing military operations pose risks to supply chains, workforce availability, and the ability to import materials or ship devices.
- Nasdaq Compliance: The company received a deficiency letter from Nasdaq on October 9, 2024, for failing to meet the $1.00 minimum bid price requirement for 30 consecutive days. Failure to regain compliance could result in delisting.
- Contingent Bonuses: Certain executive bonuses contingent on capital raising were triggered and expensed in Q3 2024 after the company raised $3.0 million in new funds.
Investor Verification Checklist
- Liquidity Runway: Verify the exact timeline for cash depletion given the "less than one year" warning and the burn rate of ~$2.7 million per quarter.
- Nasdaq Compliance Plan: Confirm the specific steps management is taking to regain compliance with the $1.00 minimum bid price requirement to avoid delisting.
- Capital Raise Terms: Review the terms of recent equity issuances (Series E and F options, ATM) to assess dilution impact on existing shareholders.
- Regulatory Milestones: Monitor the status of the 510(k) submission and FDA clearance timeline, as delays could further strain cash reserves.
- Israel Operations: Assess the current status of the war's impact on the company's Israeli R&D facilities and supply chain logistics.